



**JUBILANT**  
**LIFESCIENCES**

May 25, 2016

**BSE Limited**

Corporate Service Department  
1<sup>st</sup> Floor, New Trading Ring  
Rotunda Building, P.J. Tower  
Dalal Street, Fort  
Mumbai - 400 001

**The National Stock Exchange of India Ltd.**

Exchange Plaza,  
Bandra Kurla Complex  
Bandra (E)  
Mumbai – 400 051

Dear Sirs,

We enclose a copy of the Announcement being issued by the Company.

This is for your kind information and records.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

Rajiv Shah  
Company Secretary

Encl.: as above

A Jubilant Bhartia Company

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Life Sciences Ltd.**  
1A, Sector 16A, Noida – 201301, India  
Tel.: +91 120 4361000  
[www.jubl.com](http://www.jubl.com)

## **Jubilant Life Sciences receives ANDA approval for 0.9% Sodium Chloride Injection USP**

***Noida (UP), India, Wednesday, May 25, 2016***

Jubilant Life Sciences Ltd, an integrated global Pharmaceuticals and Life Sciences Company, has announced that its subsidiary Jubilant HollisterStier LLC, Spokane, Washington, has received Abbreviated New Drug Application (ANDA) approval for **0.9% Sodium Chloride Injection USP, 3 mL and 10 mL vials**, the generic equivalent of Sodium Chloride 0.9% in Plastic Container, of Hospira, Inc., which is indicated only for diluting or dissolving drugs for intravenous, intramuscular or subcutaneous injection, according to instructions of the manufacturer of the drug to be administered.

This is the first ANDA approval in injectables received by the company. We have filed two injectables and one ophthalmic product as on March 31, 2016.

### **About Jubilant Life Sciences Limited**

Jubilant Life Sciences Limited is an integrated global Pharmaceutical and Life Sciences Company engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Life Science Ingredients. It also provides Services in Contract Manufacturing of Sterile Products and Drug Discovery Solutions. The Company's strength lies in its unique offerings of Pharmaceutical and Life Sciences products and services across the value chain. With 12 world-class manufacturing facilities in India, US and Canada and a team of about 6,200 multicultural people across the globe, the Company is committed to deliver value to its customers spread across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

### **For more information please contact:**

#### ***For Investors***

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1002 / 1021  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)  
[anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Siddharth Rangnekar / Karl Kolah  
Citigate Dewe Rogerson  
Tel: +91 22 6645 1209 / 1220  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)

#### ***For Media***

Sudhakar Safaya / Neha Garg  
Jubilant Life Sciences Limited  
Ph: +91-120 436 1062 / 1067  
E-mail: [sudhakar\\_safaya@jubl.com](mailto:sudhakar_safaya@jubl.com)  
[neha\\_garg@jubl.com](mailto:neha_garg@jubl.com)

Kanika Mittal  
Perfect Relations  
Ph: +91 9899574833  
E-mail: [kmittal@perfectrelations.com](mailto:kmittal@perfectrelations.com)



*Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.*